The urinary copper concentration reverted to less than 1 26 [imol24 hours; and the serum copper concentration decreased further during zinc sulphate treatment. In one child the rise in 24 hour urinary copper excretion observed after a challenge dose of D-penicillamine (±20 mg/kg) remained constant throughout the period of observation while the liver copper content fell from 1460 tg/g dry weight to 890 [ig/g dry weight. In the other patient, however, the liver copper content as well as the 24 hour urinary copper excretion increased after D-penicillamine challenge during the third year of treatment. We conclude that zinc sulphate is a low toxic and well tolerated alternative for D-penicillamine. Serum and 24 hour urine for zinc and copper assays as well as liver biopsy specimens were collected in metal free containers. All metal analyses were performed in duplicate by atomic absorption spectrophotometry. The intravenous radiocopper test was performed according to a modification of a previously described protocol.9 64Cu (half life 12*7 hours) was used at a dose of 0*03 mCi (6 millirem Wilson's disease treated with D-penicillamine, provided that the previously depleted total body zinc was restored. This view is supported by the normal liver function tests, by the reversion of the urinary copper excretion to normal, and by the maintenance of a low serum copper concentration during three years of zinc sulphate treatment in both children described here. The small but consistent rise in urinary copper excretion after a challenge dose of D-penicillamine in patient 1 leads to the same conclusion. This is further confirmed by the histological course of the disease in both patients and by the determination of the liver copper content in patient 1.
The increase in liver copper content observed in patient 2, is however, disturbing, and the absence of a concomitant increase 
